σ receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets

被引:12
作者
Chan, SLF [1 ]
Morgan, NG [1 ]
机构
[1] Keele Univ, Dept Biol Sci, Cellular Pharmacol Grp, Keele ST5 5BG, Staffs, England
基金
英国惠康基金;
关键词
imidazoline receptor; efaroxan; sigma receptor; insulin secretion; DTG(N; N; '-di-(o-tolyl)guanidine); (+)-3-PPP ((R)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine);
D O I
10.1016/S0014-2999(98)00263-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of two potent sigma receptor agonists (+)-3-PPP ((R)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine) and DTG (N,N'-di-(o-tolyl)guanidine) on the insulin secretory responses in rat islets of Langerhans were investigated. Both sigma receptor ligands were able to potentiate the insulin secretory response of islets incubated at 6 mM glucose, in a dose-dependent manner and were also able to reverse the effects of diazoxide on insulin release. When islets were treated with efaroxan, a well-characterised imidazoline insulin secretagogue, and either (+)-3-PPP or DTG together, there was an unexpected and profound absence of stimulation of insulin release as compared to when islets were incubated with each compound alone. Experiments performed with islets where there was desensitization of DTG/sigma receptor or efaroxan/imidazoline binding site mediated responses suggest that at least two distinct receptor systems appear to be involved. The complex interactions of these two classes of drug require further investigation. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:267 / 272
页数:6
相关论文
共 29 条
[1]  
Alemany R, 1995, Ann N Y Acad Sci, V763, P506, DOI 10.1111/j.1749-6632.1995.tb32442.x
[2]  
BREMER M, 1989, SOC NEUR ABST, V15
[3]   ANTAGONISM OF THE STIMULATORY EFFECTS OF EFAROXAN AND GLIBENCLAMIDE IN RAT PANCREATIC-ISLETS BY THE IMIDAZOLINE, RX801080 [J].
BROWN, CA ;
CHAN, SLF ;
STILLINGS, MR ;
SMITH, SA ;
MORGAN, NG .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1017-1022
[4]   THE IMIDAZOLINE SITE INVOLVED IN CONTROL OF INSULIN-SECRETION - CHARACTERISTICS THAT DISTINGUISH IT FROM I-1-SITE AND I-2-SITE [J].
CHAN, SLF ;
BROWN, CA ;
SCARPELLO, KE ;
MORGAN, NG .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (04) :1065-1070
[5]   THE ALPHA-2-ADRENOCEPTOR ANTAGONIST EFAROXAN MODULATES K+ATP CHANNELS IN INSULIN-SECRETING CELLS [J].
CHAN, SLF ;
DUNNE, MJ ;
STILLINGS, MR ;
MORGAN, NG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 204 (01) :41-48
[6]   Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors [J].
Chan, SLF ;
Pallett, AL ;
Clews, J ;
Ramsden, CA ;
Morgan, NG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (2-3) :241-244
[7]   STIMULATION OF INSULIN-SECRETION BY EFAROXAN MAY INVOLVE INTERACTION WITH POTASSIUM CHANNELS [J].
CHAN, SLF ;
MORGAN, NG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 176 (01) :97-101
[8]   ROLE OF ALPHA-2-ADRENOCEPTORS AND IMIDAZOLINE-BINDING SITES IN THE CONTROL OF INSULIN-SECRETION [J].
CHAN, SLF .
CLINICAL SCIENCE, 1993, 85 (06) :671-677
[9]  
Dunne M J, 1995, Ann N Y Acad Sci, V763, P243, DOI 10.1111/j.1749-6632.1995.tb32410.x
[10]   BLOCK OF ATP-REGULATED POTASSIUM CHANNELS BY PHENTOLAMINE AND OTHER ALPHA-ADRENOCEPTOR ANTAGONISTS [J].
DUNNE, MJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (04) :1847-1850